Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Incidence of and survival following brain metastases among women with inflammatory breast cancer
Annals of Oncology, Volume 21, No. 12, Year 2010
Notification
URL copied to clipboard!
Description
Background: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). Patients and methods: Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan-Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases. Results: Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months. Conclusion: Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Authors & Co-Authors
Dawood, Shaheenah S.
United States, Houston
The University of Texas Md Anderson Cancer Center
United Arab Emirates, Dubai
Dubai Hospital
Ueno, Naoto Tada
United States, Houston
The University of Texas Md Anderson Cancer Center
Valero, Vicente V.
United States, Houston
The University of Texas Md Anderson Cancer Center
Andreopoulou, E.
United States, Houston
The University of Texas Md Anderson Cancer Center
Hsu, L.
United States, Houston
The University of Texas Md Anderson Cancer Center
Lara, J.
United States, Houston
The University of Texas Md Anderson Cancer Center
Woodward, Wendy A.
United States, Houston
The University of Texas Md Anderson Cancer Center
Buchholz, Thomas A.
United States, Houston
The University of Texas Md Anderson Cancer Center
Hortobágyi, Gabriel N.
United States, Houston
The University of Texas Md Anderson Cancer Center
Cristofanilli, Massimo A.
United States, Houston
The University of Texas Md Anderson Cancer Center
Statistics
Citations: 29
Authors: 10
Affiliations: 2
Identifiers
Doi:
10.1093/annonc/mdq239
ISSN:
09237534
e-ISSN:
15698041
Research Areas
Cancer
Environmental
Study Design
Cohort Study
Participants Gender
Female